+13.1%
GSK vs INVH
+1.1%
+12.0%
-22.4%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | INVH | Excess | Alpha |
|---|---|---|---|---|
| 1D | +5.0% | +3.6% | +1.4% | +3.7% |
| 7D | +4.9% | +3.1% | +1.9% | +3.8% |
| 30D | +9.9% | +5.8% | +4.1% | +7.9% |
| 3M | +0.2% | -8.5% | +8.7% | +2.7% |
| 6M | +2.3% | -1.3% | +3.7% | +2.9% |
| YTD | +7.1% | +2.6% | +4.5% | +6.3% |
| 1Y | +13.1% | +0.7% | +12.4% | +11.6% |
| All | +13.1% | +1.1% | +12.0% | +11.6% |
Cumulative growth
Daily Returns
Daily percentage return beside INVH.
Daily Out/Under-Performance
Portfolio return minus INVH return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × INVH return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded INVH wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling